- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05835726
Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. (DILEMMA)
Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients (DILEMMA).
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Luciana Teofili
- Phone Number: +39 06 30154180
- Email: luciana.teofili@unicatt.it
Study Contact Backup
- Name: Caterina Giovanna Valentini
- Email: caterinagiovanna.valentini@policlinicogemelli.it
Study Locations
-
-
-
Rome, Italy, 00168
- Recruiting
- Fondazione Policlinico Universitario A.Gemelli IRCCS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Cases (prospective cohort): Patients with newly diagnosed multiple myeloma candidate to stem cell mobilization, collection, and autologous stem cell transplant who receive a Daratumumab-containing induction regimen.
Controls: Patients with newly diagnosed multiple myeloma who received standard VTD induction, subsequent stem cell mobilization, and tandem autologous stem cell transplant before the introduction of daratumumab in our local practice from January 2020 to December 2021.
Description
Inclusion Criteria:
- Age ≥ 18 years.
- NDMM candidate to stem cell mobilization, collection, and ASCT who received a Daratumumab-containing induction regimen.
- Signed written informed consent to study participation.
Exclusion Criteria:
- Age <18 y.o.
- Inability to obtain written informed consent.
- Patients not proceeding to stem cell mobilization because of disease progression.
- Patients not eligible for high-dose cyclophosphamide according to baseline cardiologic evaluation.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cases (prospective cohort)
Patients who fulfill the inclusion criteria (newly diagnosed multiple myeloma patients undergoing daratumumab-containing induction regimens).
|
NDMM (newly diagnosed multiple myeloma) who fulfill the inclusion criteria, candidate to stem cell mobilization, collection, and autologous stem cell transplant who receive a Daratumumab-containing induction regimen.
Other Names:
|
Controls
Patients with newly diagnosed multiple myeloma who received standard VTD (VTD:bortezomib-thalidomide and dexamethasone) induction, subsequent stem cell mobilization, and tandem autologous stem cell transplant before the introduction of daratumumab in our local practice from January 2020 to December 2021.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the difference in the mean number of collected CD34+ cells/kg during total harvest between Daratumumab and control group.
Time Frame: 12 months
|
To assess the difference in the mean number of collected CD34+ cells/kg during total harvest between Daratumumab and control group.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion (%) of patients achieving at least two minimum transplant doses (4x10^6 CD34+ cells/kg) at first day of apheresis in Daratumumab versus control group.
Time Frame: 12 months
|
Proportion (%) of patients achieving at least two minimum transplant doses (4x10^6 CD34+ cells/kg) at first day of apheresis in Daratumumab versus control group.
|
12 months
|
Proportion (%) of patients who received plerixafor rescue for poor mobilization in Daratumumab versus control group.
Time Frame: 12 months
|
Proportion (%) of patients who received plerixafor rescue for poor mobilization in Daratumumab versus control group.
|
12 months
|
Graft composition in Daratumumab group in term of concentration of CD34+ cells x10^6/kg, TNC (total nucleated cells) x 10^8/kg, and MNC (mononuclear cells) x 10^8/kg.
Time Frame: 12 months
|
Graft composition in Daratumumab group in term of concentration of CD34+ cells x10^6/kg, TNC (total nucleated cells) x 10^8/kg, and MNC (mononuclear cells) x 10^8/kg.
|
12 months
|
Rate (%) of CD38 expression and clonogenic potential of collected CD34+ cells in both groups.
Time Frame: 12 months
|
Rate (%) of CD38 expression and clonogenic potential of collected CD34+ cells in both groups.
|
12 months
|
To compare transplant outcome in term of time (days) to platelets and neutrophils engraftment in Daratumumab versus control group.
Time Frame: 12 months
|
To compare transplant outcome in term of time (days) to platelets and neutrophils engraftment in Daratumumab versus control group.
|
12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Antineoplastic Agents
- Daratumumab
Other Study ID Numbers
- 5446
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Daratumumab
-
Janssen Research & Development, LLCActive, not recruitingSmoldering Multiple MyelomaUnited States, Netherlands, Belgium, Canada, Israel, Czechia, Denmark, Japan, Hungary, Turkey, United Kingdom, Spain, Sweden, France, Germany, Italy, Russian Federation, Poland, Mexico, Australia, Brazil, Greece, Argentina, Norway
-
Boston Medical CenterJanssen PharmaceuticalsCompleted
-
National Cancer Institute (NCI)RecruitingLymphoma, Primary EffusionUnited States
-
University of ArkansasJanssen Scientific Affairs, LLCRecruiting
-
Incyte CorporationTerminatedRelapsed or Refractory Multiple MyelomaUnited States, Spain, Germany
-
Ostfold Hospital TrustOdense University Hospital; Oslo University Hospital; Haukeland University Hospital and other collaboratorsActive, not recruiting
-
Ronald WittelesCompletedHeart Transplant Failure and Rejection | AllosensitizationUnited States
-
Charite University, Berlin, GermanyJanssen-Cilag G.m.b.H; Labor Berlin-Charité Vivantes G.m.b.H; Deutsches Rheuma-Forschungszentrum... and other collaboratorsNot yet recruiting
-
Memorial Sloan Kettering Cancer CenterTrillium Therapeutics Inc.Active, not recruitingMultiple MyelomaUnited States
-
Marc L Gordon, MDJanssen Scientific Affairs, LLCCompletedAlzheimer DiseaseUnited States